ALHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALHC is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to act now. The company has strong revenue growth and improving operating metrics, but the stock is still showing weak technical momentum, mixed analyst positioning, and heavy hedge fund selling. It is better to wait for clearer price strength or a more attractive entry than buy immediately at this level.
The technical picture is weak. MACD histogram is negative and expanding, which signals bearish momentum. RSI_6 at 25.411 suggests the stock is oversold, but not yet showing a strong reversal confirmation. Moving averages are converging, which often means the stock is at a decision point, but the current trend is not clearly bullish. Price at 18.23 is sitting just below the pivot area (20.192) and very close to S1 (18.354), so the stock is trading near short-term support rather than breaking out. The provided trend model also points to soft near-term performance, with downside expected over the next week and month.
["Q1 2026 revenue grew 33.26% YoY to $1.235B.", "Health plan membership grew 31% YoY to 284,800 in Q1 2026.", "Adjusted gross profit of $146M and adjusted EBITDA of $38M show operational progress.", "Auto adjudication rate improved to over 60% due to AI-powered contract management.", "Management raised 2026 membership guidance to 294,000-299,000 and guided Q2 revenue to $1.30B-$1.32B.", "Options positioning is bullish with very low put-call ratios."]
["MACD remains negative and is worsening, signaling weak momentum.", "The stock is below the pivot level and not showing a clean uptrend.", "Hedge funds are selling heavily, with selling up 1606.19% over the last quarter.", "Analysts have mixed views: one Strong Buy was cut to a lower target, while others are Neutral/Equal Weight.", "Net income and EPS declined sharply YoY in the latest quarter.", "Short-term modeled price trend suggests slight downside over the next week and month."]
In Q1 2026, Alignment Healthcare delivered strong top-line growth, with revenue up 33.26% YoY to about $1.236B. Membership growth was also strong at 31% YoY, and gross margin improved to 11.06%. The quarter was not as strong on the bottom line, since net income fell to $11.4M and EPS dropped to $0.05 YoY. Overall, the latest quarter shows good growth and improving efficiency, but profitability is still uneven.
Recent analyst trends are mixed to mildly positive on targets but not on stance. Raymond James lowered its target to $22 from $27 while keeping a Strong Buy, citing a solid quarter but valuation concerns and minor hiccups. UBS raised its target to $22 from $21 but kept Neutral, and Barclays raised its target to $19 from $18 with Equal Weight. The Wall Street pros view is therefore split: bulls like the growth story, while cautious analysts see valuation and execution risk. No recent politician or congress trading activity was reported.
